A PYMNTS Company

US: Pharmaceutical joint venture runs ahead without objection

By  |  August 14, 2013
US: Pharmaceutical joint venture runs ahead without objection

Biotechnology firm Amgen announced a joint venture with pharmaceutical company Servier in a deal that gives Amgen the rights to heart drug ivabradine, approved in Europe, in the US. In return, Servier gained EU commercialization rights to a drug developed by Amgen, which has reached phase II testing in the US. The waiting period for antitrust regulators to review the deal has passed, say reports. Under terms of the joint venture, Amgen has the rights to chronic heart failure drug ivabradine, under the brand name in Europe of Procorain and will pay Servier $50 million for the rights. Additional financial details were not disclosed.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Full Content: PharmaTimes

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.